Jump To Top

groundrushairsports

You are here:
Home / Health News / Germany says vaccine rollout on track despite CureVac trial flop

Germany says vaccine rollout on track despite CureVac trial flop

FILE PHOTO: German biotechnology company CureVac’s vaccination against the coronavirus disease (COVID-19) is given to a volunteer at the start of a clinical test series in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach

BERLIN (Reuters) – A failure of German biotech CureVac to meet its efficacy goal in a late-stage trial for its COVID-19 vaccine will not impact the speed of Germany’s vaccination rollout, the health ministry said on Thursday.

“The announcement does not have an impact on the speed of our vaccination rollout,” a health ministry spokesperson said, declining to comment on the study results.

CureVac said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.

Source: Read Full Article

Related posts:
  1. WHO lists AstraZeneca/Oxford COVID-19 vaccine for emergency use
  2. Pfizer seeks to store vaccine at higher temperatures, easing logistics
  3. Germany approves three COVID home test kits to help chart way out of lockdown
  4. Vaccine supply chains disrupted by U.S. restrictions: Curevac co-founder
  • Posted on June 17, 2021
RELATED NEWS
The Ultimate Guide to Hydrafacial Treatment
Inside the Pentagon’s painfully slow effort to clean up decades of PFAS contamination
Stem cell heart tissue model paves the way for better understanding of tachycardia
Antimicrobial resistance leads to more deaths and illnesses in the WHO African region than anywhere else: Study